Published in J Biomed Biotechnol on July 15, 2012
Alternatives to animal testing: A review. Saudi Pharm J (2013) 0.80
Scope and limitations of yeast as a model organism for studying human tissue-specific pathways. BMC Syst Biol (2015) 0.75
Phosphorylation of the 19S regulatory particle ATPase subunit, Rpt6, modifies susceptibility to proteotoxic stress and protein aggregation. PLoS One (2017) 0.75
A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature (2000) 47.15
Functional profiling of the Saccharomyces cerevisiae genome. Nature (2002) 36.10
A comprehensive two-hybrid analysis to explore the yeast protein interactome. Proc Natl Acad Sci U S A (2001) 33.71
Systematic genetic analysis with ordered arrays of yeast deletion mutants. Science (2001) 24.48
Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 21.65
A genome-wide transcriptional analysis of the mitotic cell cycle. Mol Cell (1998) 19.67
Global analysis of protein activities using proteome chips. Science (2001) 13.74
[URE3] as an altered URE2 protein: evidence for a prion analog in Saccharomyces cerevisiae. Science (1994) 10.94
Regulation of RAD53 by the ATM-like kinases MEC1 and TEL1 in yeast cell cycle checkpoint pathways. Science (1996) 8.71
Epidemiology of Parkinson's disease. Lancet Neurol (2006) 8.13
Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science (2006) 7.72
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell (2005) 6.31
A century of Alzheimer's disease. Science (2006) 5.84
Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat Chem Biol (2007) 5.78
Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci (2007) 5.72
Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science (2010) 5.42
Reconstitution of gamma-secretase activity. Nat Cell Biol (2003) 4.66
Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science (2003) 4.45
Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science (1997) 3.94
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med (2004) 3.93
Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc Natl Acad Sci U S A (2000) 3.82
The m-AAA protease defective in hereditary spastic paraplegia controls ribosome assembly in mitochondria. Cell (2005) 3.72
Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet (2009) 3.59
A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A (2008) 3.46
Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci U S A (2000) 3.43
The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci U S A (2007) 3.39
Emerging principles of conformation-based prion inheritance. Annu Rev Biochem (2004) 3.36
TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem (2009) 3.29
Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. Nat Genet (2009) 3.06
Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science (2003) 2.89
The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One (2010) 2.78
Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J Cell Biol (2002) 2.76
Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science (2011) 2.66
Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci U S A (2006) 2.59
The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions. Nat Cell Biol (2006) 2.58
Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. Curr Opin Neurobiol (2011) 2.48
A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet (2005) 2.28
Effects of Q/N-rich, polyQ, and non-polyQ amyloids on the de novo formation of the [PSI+] prion in yeast and aggregation of Sup35 in vitro. Proc Natl Acad Sci U S A (2004) 2.27
Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech (2009) 2.16
A yeast model of FUS/TLS-dependent cytotoxicity. PLoS Biol (2011) 1.95
The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol (2004) 1.92
Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol (2002) 1.90
A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci U S A (2005) 1.88
Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol (2009) 1.88
A network of protein interactions determines polyglutamine toxicity. Proc Natl Acad Sci U S A (2006) 1.85
Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. Genes Dev (2008) 1.81
The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol (2010) 1.80
Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue. Nat Genet (1997) 1.79
Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum Mol Genet (2006) 1.77
Abnormal proteins can form aggresome in yeast: aggresome-targeting signals and components of the machinery. FASEB J (2008) 1.74
Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A (2006) 1.73
The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J Neurol (2009) 1.68
GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet (2010) 1.63
The C-terminus of the beta protein is critical in amyloidogenesis. Ann N Y Acad Sci (1993) 1.61
Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen (2010) 1.60
Altered transcription in yeast expressing expanded polyglutamine. Proc Natl Acad Sci U S A (2001) 1.58
A systematic library for comprehensive overexpression screens in Saccharomyces cerevisiae. Nat Methods (2008) 1.56
Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease. J Mol Biol (2005) 1.51
Alpha-synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. Mol Biol Cell (2008) 1.48
Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J Mol Biol (2006) 1.47
Modulation of prion-dependent polyglutamine aggregation and toxicity by chaperone proteins in the yeast model. J Biol Chem (2005) 1.46
Modelling neurodegeneration in Saccharomyces cerevisiae: why cook with baker's yeast? Nat Rev Neurosci (2010) 1.46
Isolation of drugs active against mammalian prions using a yeast-based screening assay. Nat Biotechnol (2003) 1.45
The proteasome in brain aging. Ageing Res Rev (2002) 1.35
Critical role of the proline-rich region in Huntingtin for aggregation and cytotoxicity in yeast. J Biol Chem (2006) 1.33
Functional mitochondria are required for alpha-synuclein toxicity in aging yeast. J Biol Chem (2008) 1.28
Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment. Proc Natl Acad Sci U S A (2002) 1.24
Endocytosis machinery is involved in aggregation of proteins with expanded polyglutamine domains. FASEB J (2007) 1.22
Aggregation of expanded polyglutamine domain in yeast leads to defects in endocytosis. Mol Cell Biol (2003) 1.21
Intracellular accumulation of amyloid-Beta - a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease. Front Aging Neurosci (2010) 1.20
Rapid selection of cyclic peptides that reduce alpha-synuclein toxicity in yeast and animal models. Nat Chem Biol (2009) 1.19
Review: Familial Parkinson's disease--genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neuropathol Appl Neurobiol (2008) 1.17
Characterization of three yeast copper-zinc superoxide dismutase mutants analogous to those coded for in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (1994) 1.16
Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. Hum Mol Genet (2006) 1.16
Phosphorylation, lipid raft interaction and traffic of alpha-synuclein in a yeast model for Parkinson. Biochim Biophys Acta (2008) 1.15
Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease. Acta Neuropathol (2011) 1.13
Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. J Biol Chem (2007) 1.11
A yeast model for the study of Batten disease. Proc Natl Acad Sci U S A (1998) 1.10
Sequence Determinants for Amyloid Fibrillogenesis of Human alpha-Synuclein. J Mol Biol (2007) 1.09
Alpha-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast. Genetics (2005) 1.09
The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast. J Mol Biol (2009) 1.08
Molecular pathogenesis of Parkinson's disease: update. J Neurol Neurosurg Psychiatry (2011) 1.07
Expression of human FUS/TLS in yeast leads to protein aggregation and cytotoxicity, recapitulating key features of FUS proteinopathy. Protein Cell (2011) 1.07
Gene dosage and pathogenesis of Parkinson's disease. Trends Mol Med (2005) 1.04
A yeast-based model of alpha-synucleinopathy identifies compounds with therapeutic potential. Biochim Biophys Acta (2005) 1.03
YGR198w (YPP1) targets A30P alpha-synuclein to the vacuole for degradation. J Cell Biol (2007) 1.00
Characterization of alpha-synuclein aggregation and synergistic toxicity with protein tau in yeast. FEBS J (2005) 1.00
Alpha-synuclein alters proteasome function, protein synthesis, and stationary phase viability. J Biol Chem (2005) 1.00
Modulation of Abeta42 low-n oligomerization using a novel yeast reporter system. BMC Biol (2006) 0.97
Alzheimer's disease meets the ubiquitin-proteasome system. Trends Mol Med (2004) 0.97
Aggregation of α-synuclein in S. cerevisiae is associated with defects in endosomal trafficking and phospholipid biosynthesis. J Mol Neurosci (2010) 0.96
alpha-Synuclein budding yeast model: toxicity enhanced by impaired proteasome and oxidative stress. J Mol Neurosci (2006) 0.96
Hsp104 targets multiple intermediates on the amyloid pathway and suppresses the seeding capacity of Abeta fibrils and protofibrils. J Mol Biol (2008) 0.96
Involvement of cell surface glycosyl-phosphatidylinositol-linked aspartyl proteases in alpha-secretase-type cleavage and ectodomain solubilization of human Alzheimer beta-amyloid precursor protein in yeast. J Biol Chem (1998) 0.96
Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases. Curr Pharm Biotechnol (2010) 0.95
Defects in very long chain fatty acid synthesis enhance alpha-synuclein toxicity in a yeast model of Parkinson's disease. PLoS One (2011) 0.94
Suppression of polyglutamine-induced cytotoxicity in Saccharomyces cerevisiae by enhancement of mitochondrial biogenesis. FASEB J (2009) 0.94
Reciprocal efficiency of RNQ1 and polyglutamine detoxification in the cytosol and nucleus. Mol Biol Cell (2009) 0.94
Novel suppressors of alpha-synuclein toxicity identified using yeast. Hum Mol Genet (2008) 0.94
Structures of telomerase subunits provide functional insights. Biochim Biophys Acta (2009) 0.99
Mortality due to Vegetation Fire-Originated PM2.5 Exposure in Europe-Assessment for the Years 2005 and 2008. Environ Health Perspect (2016) 0.92
[HTLV 1/2 infection: prenatal performance as a disease control strategy in State of Mato Grosso do Sul]. Rev Soc Bras Med Trop (2008) 0.89
New insights into cancer-related proteins provided by the yeast model. FEBS J (2012) 0.87
Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach. Biochem Pharmacol (2013) 0.87
Modulation of Bax mitochondrial insertion and induced cell death in yeast by mammalian protein kinase Cα. Exp Cell Res (2010) 0.85
SNaPaer: a practical single nucleotide polymorphism multiplex assay for genotyping of Pseudomonas aeruginosa. PLoS One (2013) 0.85
Distinct regulation of p53-mediated apoptosis by protein kinase Cα, δ, ε and ζ: Evidence in yeast for transcription-dependent and -independent p53 apoptotic mechanisms. Exp Cell Res (2011) 0.82
Telomere maintenance as a target for drug discovery. J Med Chem (2013) 0.82
Differential regulation of p53 function by protein kinase C isoforms revealed by a yeast cell system. FEBS Lett (2009) 0.82
Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile. J Med Chem (2009) 0.82
The importance of humanized yeast to better understand the role of bcl-2 family in apoptosis: finding of novel therapeutic opportunities. Curr Pharm Des (2011) 0.81
Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity. FEBS J (2013) 0.80
BRACO19 analog dimers with improved inhibition of telomerase and hPot 1. Bioorg Med Chem (2009) 0.79
Microglia P2Y₆ receptors mediate nitric oxide release and astrocyte apoptosis. J Neuroinflammation (2014) 0.78
Production and purification of theVP1 capsid protein of a novel canine norovirus using the Saccharomyces cerevisiae expression system. J Microbiol Methods (2012) 0.77
Using yeast to uncover the regulation of protein kinase Cδ by ceramide. FEMS Yeast Res (2013) 0.77
Effects of Tributyltin and Other Retinoid Receptor Agonists in Reproductive-Related Endpoints in the Zebrafish (Danio rerio). J Toxicol Environ Health A (2015) 0.76
Endocytosis inhibition during H2O2-induced apoptosis in yeast. FEMS Yeast Res (2012) 0.76
Α-mangostin and gambogic acid as potential inhibitors of the p53-MDM2 interaction revealed by a yeast approach. J Nat Prod (2013) 0.76
Interference of aging media on the assessment of yeast chronological life span by propidium iodide staining. Folia Microbiol (Praha) (2012) 0.75
New therapeutic strategies for cancer and neurodegeneration emerging from yeast cell-based systems. Curr Pharm Des (2012) 0.75
Aspartic vinyl sulfones: inhibitors of a caspase-3-dependent pathway. Eur J Med Chem (2011) 0.75
Differential activation of protein kinase C isoforms by euxanthone, revealed by an in vivo yeast phenotypic assay. Planta Med (2002) 0.75